The case for long-read sequencing for the future of genomic newborn screening
Genetics in Medicine Open
Seth I. Berger, Laura M. Amendola, Susan Toomey, Changrui Xiao, Jonathan LoTempio, Emmanuèle Délot, Eric Vilain, Marcy Richardson, Jessie Grzybowski, Rachid Karam, Steven M. Lipkin, Kelly Hagman
Abstract
Newborn screening is a highly successful public health program, that screens all infants at birth, regardless of clinical symptoms, for conditions in which presymptomatic diagnosis permits early intervention in care. In recent years, expanding newborn screening through the integration of genome sequencing with standard practices has been explored. Several studies have demonstrated the feasibility of genome sequencing to decrease infant and early childhood morbidity while reducing costs, providing increased diagnostic specificity, and enabling detection of additional conditions.
All studies to date that we are aware of have focused on using short-read genome sequencing (SRS) as the assay of choice because of the maturity and cost effectiveness of SRS in clinical workflows. However, as the economics of sequencing technologies continue to evolve, there are clear benefits of long-read sequencing (LRS) in the newborn screening space compared to SRS. In this commentary, we discuss broad considerations for integrating genomic testing into newborn screening and the technical benefits of LRS for genomic newborn screening, namely as it relates to decreased false positive rates, improved diagnostic sensitivity for interpretable variants, as well as increased technical capacity for detection of disorders both currently on the Recommended Universal Screening Panel (RUSP) and disorders not currently screened due to purely technical reasons. While there are many challenges to overcome and a need for proof of concept implementation, we propose the exploration of LRS as an accurate and more future-proof testing platform for genomic newborn screening in future research.
Related publications